|Articles|October 15, 2009

Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast

Listen to a preview of Drugs, Devices or Data – Which is Most Valuable? Webcast

Download Adobe Flash PlayerRegister Free for the Webcast

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

From Ambition to Advantage: How Life Sciences Leaders Are Scaling AI

ByShravan Kotakonda

December 10th 2025

Aidoc Submits Breakthrough-Designated Multi-Triage Device for FDA Approval

ByNicholas Jacobus

November 25th 2025

How Technology is Moving the Industry Away from Animal Testing: Q&A with Dr. Jo Varshney

ByMike Hollan

November 25th 2025

Agentic AI Will Transform the Business of Life Sciences

ByDavid Rosner

November 18th 2025

Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity

ByAnup Gupta

November 6th 2025

Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast

Newsletter

Related Content

From Ambition to Advantage: How Life Sciences Leaders Are Scaling AI

Aidoc Submits Breakthrough-Designated Multi-Triage Device for FDA Approval

How Technology is Moving the Industry Away from Animal Testing: Q&A with Dr. Jo Varshney

Agentic AI Will Transform the Business of Life Sciences

Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity

Trending on PharmExec

Brent Saunders: Eyeing New Horizons

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial

The GLP-1 Gold Rush

FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies